The House Dust Mite Allergy drugs in development market research report provides comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for House Dust Mite Allergy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued products.

GlobalData tracks 13 drugs in development for House Dust Mite Allergy by 13 companies/universities/institutes. The top development phase for House Dust Mite Allergy is preclinical with three drugs in that stage. The House Dust Mite Allergy pipeline has 11 drugs in development by companies and two by universities/ institutes. Some of the companies in the House Dust Mite Allergy pipeline products market are: Allergy Therapeutics, Genetic Immunity and Vanderbilt University Medical Center.

The key targets in the House Dust Mite Allergy pipeline products market include Der p 2 Allergen.

The key mechanisms of action in the House Dust Mite Allergy pipeline product include 0 with 0 drug in 0. The House Dust Mite Allergy pipeline products include seven routes of administration with the top ROA being Subcutaneous and three key molecule types in the House Dust Mite Allergy pipeline products market including Allergenics (Allergen), and Vaccine.

House Dust Mite Allergy overview

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose, and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants, and corticosteroids.

For a complete picture of House Dust Mite Allergy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.